Article
The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.
Diabetes - 1 Sept 2013
't Hart Leen M, Fritsche Andreas, Nijpels Giel, van Leeuwen Nienke, Donnelly Louise A, Dekker Jacqueline M, Alssema Marjan, Fadista Joao, Carlotti Françoise, Gjesing Anette P, Palmer Colin N A, van Haeften Timon W, Herzberg-Schäfer Silke A, Simonis-Bik Annemarie M C, Houwing-Duistermaat Jeanine J, Helmer Quinta, Deelen Joris, Guigas Bruno, Hansen Torben, Machicao Fausto, Willemsen Gonneke, Heine Robert J, Kramer Mark H H, Holst Jens J, de Koning Eelco J P, Häring Hans-Ulrich, Pedersen Oluf, Groop Leif, de Geus Eco J C, Slagboom P Eline, Boomsma Dorret I, Eekhoff Elisabeth M W, Pearson Ewan R, Diamant Michaela
Abstract excerpt
The incretin hormone glucagon-like peptide 1 (GLP-1) promotes glucose homeostasis and enhances β-cell function. GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the physiological inactivation of endogenous GLP-1, are used for the treatment of type 2 diabetes. Using the Metabochip, we identified three novel genetic loci with large effects (30-40%) on GLP-1-stimulated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.